Examination of the effectiveness of direct oral anticoagulants in comparison to warfarin in an obese population
RM Watson, CB Smith, EF Crannage… - Journal of Pharmacy …, 2022 - journals.sagepub.com
Background: While commonly prescribed today, direct oral anticoagulants (DOACs) have
historically been avoided in patients with class III obesity or a weight> 120 kg due to limited …
historically been avoided in patients with class III obesity or a weight> 120 kg due to limited …
Direct oral anticoagulants and warfarin safety in rural patients with obesity
ZR Caverley, RJ Bindler, P Soh… - The American journal of the …, 2023 - Elsevier
Abstract Background Direct oral anticoagulants (DOACs) are often used in patients with
atrial fibrillation or flutter instead of warfarin and although supporting evidence is limited …
atrial fibrillation or flutter instead of warfarin and although supporting evidence is limited …
Prescribing DOACs with specific patient populations in mind.
K Schleich, BE Ray - Journal of Family Practice, 2023 - search.ebscohost.com
The article focuses on the prescribing considerations of direct oral anticoagulants (DOACs)
for specific patient populations, including those with obesity, renal disease, cancer, and …
for specific patient populations, including those with obesity, renal disease, cancer, and …
[PDF][PDF] Expert Recommendations on the Usage of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) from India: Current Perspective and Future Direction
BSPPH Kumar, S George, SMVGGN Gupta, K Makineni… - 2022 - academia.edu
Non-vitamin K antagonist oral anticoagulants (NOACs) are a new class of anticoagulant
drugs used in the prevention and treatment of venous thromboembolism (VTE) and atrial …
drugs used in the prevention and treatment of venous thromboembolism (VTE) and atrial …
[HTML][HTML] Совершенствование стратегии профилактики инсульта у коморбидных пациентов с фибрилляцией предсердий и высоким риском …
АА Соколова - 2022 - dissercat.com
1.4. Понятие коморбидности, оценка ее влияния на геморрагические и
тромбоэмболические осложнения и долгосрочную приверженность терапии у …
тромбоэмболические осложнения и долгосрочную приверженность терапии у …
[PDF][PDF] in der Schlaganfallprophylaxe
T Gaspar - slaek.de
Ärzteblatt Sachsen 12/2022 - Literaturverzeichnis S. 26 Page 1 Ärzteblatt Sachsen 12|2022
T. Gaspar Literatur [1] Hanefeld M, Leonhardt W: Das metabolische Syndrom. Dt …
T. Gaspar Literatur [1] Hanefeld M, Leonhardt W: Das metabolische Syndrom. Dt …
[HTML][HTML] Direct Oral Anticoagulants for Atrial Fibrillation: Does Size Matter?
Since the introduction of direct oral anticoagulants (DOACs) more than a decade ago, these
drugs have emerged as the anticoagulant of choice for thromboembolism prevention in …
drugs have emerged as the anticoagulant of choice for thromboembolism prevention in …
[HTML][HTML] Rivaroxaban Monotherapy for Atrial Fibrillation and Coronary Artery Disease in Underweight/Obese Patients: Evidence Is Needed
D Zhou, J Fan, X Liu - JACC: Asia, 2022 - jacc.org
The number of patients with both atrial fibrillation (AF) and coronary artery disease (CAD)
has been increasing in the aging society. The medication management for these patients is …
has been increasing in the aging society. The medication management for these patients is …